MedPath

The Effect of co-administration Tamoxifen and Jaeumkanghwa-tang extract on Endometrium of Breast cancer patients

Not Applicable
Recruiting
Conditions
Neoplasms
Registration Number
KCT0002030
Lead Sponsor
Comprehensive & Integrative Medicine Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
14
Inclusion Criteria

1. Breast cancer patients taking tamoxifen more then 6 month with postmenopausal.
2. The ECOG (eastern cooperative oncology group) performance scale 0-2
3. Age: 25-75
4. No disability of cognitive function
5. Patietns who can be possible to follow up during the study
6. Patients whe have signed an approved informed consent

Exclusion Criteria

1. Patients who receive alternative therapy for treatment endometral symptoms.
2. Patients who have a history of hypersensitivity after taking Jaumganghwa-tang granuales.
3. Patients who reveive therapy for treatment gynecological diseases such as endometral cancer, ovarian cancer, endometrial hyperplasia etc.
4. Severe liver or kidney failure at liver and kidney function test.
5. Patients who are not suitable for this study.

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
size and shape of polyps; color of cervix with hysteroscopic;the range or amount of fluid accumulation ; the size and number of cyst
Secondary Outcome Measures
NameTimeMethod
vaginal bleeding, vaginal secretions with questionnaires.;blood and hormone test
© Copyright 2025. All Rights Reserved by MedPath